PMID- 38342501
OWN - NLM
STAT- MEDLINE
DCOM- 20240214
LR  - 20240226
IS  - 1471-1753 (Electronic)
IS  - 0954-6634 (Linking)
VI  - 35
IP  - 1
DP  - 2024 Dec
TI  - Dupliumab therapy for alopecia areata: a case series and review of the 
      literature.
PG  - 2312245
LID - 10.1080/09546634.2024.2312245 [doi]
AB  - BACKGROUND: A growing body of research supports the important role of the TH2 
      axis in alopecia areata (AA). Dupilumab is a humanized monoclonal antibody 
      against IL-4Ralpha that downregulates TH2 response. Although efficacy has been shown 
      in clinical trials, real-world data on the use of dupilumab in AA patients is 
      limited. OBJECTIVES: To report on a case series of 10 patients with AA who were 
      treated with dupilumab and provide real-world evidence regarding its efficacy in 
      treating severe AA. METHODS: In this retrospective single-center study, all AA 
      patients treated with dupilumab treatment were included between May 2022 and 
      October 2023. Clinical outcome measures (Severity of Alopecia Tool, SALT) and 
      adverse events (AEs) were analyzed. In addition, a literature review was 
      conducted to summarize the efficacy of AA with dupilumab and the characteristics 
      of patients previously reported in the literature. RESULTS: We identified 10 
      patients with AA who were or are being treated with dupilumab, with a median 
      (range) treatment duration of 8 (3-15) months. Of these, four patients have high 
      serum immunoglobulin E (IgE) levels (>/=200IU/ml). The mean (IQR) pretreatment SALT 
      score was 79% (52-100). Seven of 10 patients achieved at least 50% re-growth. Of 
      those who improved, the mean (IQR) percentage change in SALT score at 3 months 
      and the end of follow-up was 57% (29%-89%) and 95% (68-100), respectively. 
      Notably, seven patients (70%) had white hair regrowth, with the white hair slowly 
      decreasing over time and the proportion of pigmented black hair increasing. 
      Dupilumab was well tolerated by all patients. No adverse events were reported. 
      CONCLUSIONS: Overall, our research supports dupilumab as another candidate that 
      possesses potential benefits for AA. High levels of IgE may be not prerequisites 
      for dupilumab's successful treatment response.
FAU - Huang, Jundong
AU  - Huang J
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Hu Nan Key 
      Laboratory of Aging Biology, Changsha, China.
FAU - Jian, Jia
AU  - Jian J
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Hu Nan Key 
      Laboratory of Aging Biology, Changsha, China.
FAU - Li, Tingting
AU  - Li T
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Hu Nan Key 
      Laboratory of Aging Biology, Changsha, China.
FAU - Li, Min
AU  - Li M
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Hu Nan Key 
      Laboratory of Aging Biology, Changsha, China.
FAU - Luo, Kaifu
AU  - Luo K
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Hu Nan Key 
      Laboratory of Aging Biology, Changsha, China.
FAU - Deng, Sihan
AU  - Deng S
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Hu Nan Key 
      Laboratory of Aging Biology, Changsha, China.
FAU - Tang, Yan
AU  - Tang Y
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Hu Nan Key 
      Laboratory of Aging Biology, Changsha, China.
FAU - Liu, Fangfen
AU  - Liu F
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Hu Nan Key 
      Laboratory of Aging Biology, Changsha, China.
FAU - Zhao, Zhixiang
AU  - Zhao Z
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Hu Nan Key 
      Laboratory of Aging Biology, Changsha, China.
FAU - Shi, Wei
AU  - Shi W
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Hu Nan Key 
      Laboratory of Aging Biology, Changsha, China.
FAU - Li, Ji
AU  - Li J
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Hu Nan Key 
      Laboratory of Aging Biology, Changsha, China.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20240211
PL  - England
TA  - J Dermatolog Treat
JT  - The Journal of dermatological treatment
JID - 8918133
RN  - 37341-29-0 (Immunoglobulin E)
RN  - Diffuse alopecia
SB  - IM
MH  - Humans
MH  - Alopecia/drug therapy
MH  - *Alopecia Areata/drug therapy
MH  - Immunoglobulin E
MH  - Outcome Assessment, Health Care
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Alopecia areata
OT  - atopy
OT  - dupilumab
OT  - effectiveness
OT  - treatment
EDAT- 2024/02/12 05:43
MHDA- 2024/02/12 05:44
CRDT- 2024/02/11 20:42
PHST- 2024/02/12 05:44 [medline]
PHST- 2024/02/12 05:43 [pubmed]
PHST- 2024/02/11 20:42 [entrez]
AID - 10.1080/09546634.2024.2312245 [doi]
PST - ppublish
SO  - J Dermatolog Treat. 2024 Dec;35(1):2312245. doi: 10.1080/09546634.2024.2312245. 
      Epub 2024 Feb 11.